# Signals Article: Putative Target Q27J81 for Focal Segmental Glomerulosclerosis
Background
Focal segmental glomerulosclerosis (FSGS) is a kidney disorder characterized by scarring (sclerosis) in the glomeruli, which are the tiny filtering units within the kidney. This condition can lead to nephrotic syndrome and progressive kidney failure. FSGS is a significant cause of end-stage renal disease, and current treatment options are limited and often ineffective. Identifying novel molecular targets is crucial for developing more effective therapies.
Data-mining rationale
In a recent reanalysis effort, UniProt entry Q27J81 was identified as a putative target for FSGS. This candidate emerged from cross-referencing UniProt's reviewed human entries with expression-profiling studies in the NCBI GEO database, specifically datasets GDS:200200828, GDS:200200818, GDS:200151690, GDS:200115857, and GDS:200106828. Although Q27J81 is present in these studies, it has not been associated with any registered Phase 1 or higher clinical programs, suggesting its potential as an unexplored target.
Why prior analyses may have missed this
Many of the GEO datasets containing Q27J81 predate modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of Q27J81's potential as a target for FSGS. Additionally, the lack of integration with pathway and tissue-specific databases may have obscured its relevance.
Reasoning for further validation
To fully assess the potential of Q27J81 as a target for FSGS, several steps are recommended. Re-analyzing the matched GEO datasets using limma with Benjamini-Hochberg FDR correction will provide a more accurate picture of differential expression. Validation of top differentially-expressed genes by qPCR in an independent cohort is essential to confirm findings. Checking tissue specificity in GTEx and the Human Protein Atlas will help determine the target's relevance in the context of FSGS. Running pathway analyses using STRING or OmniPath will provide insights into the biological context of Q27J81. If validated, assessing the druggability of Q27J81 via DGIdb and ChEMBL will be crucial for potential therapeutic development.